- Surgical Implant – Next Generation contract makes Symvess more easily accessible to 170 VA hospitals –

- SAC awards require intensive product and value analysis vetting by a surgical committee and streamline the approval process by individual hospitals -

DURHAM, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (NASDAQ:HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that Symvess is now under contract with the with Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs (VA). The SAC SING (Surgical Implant – Next Generation) contract makes Symvess more easily accessible to 170 VA hospitals as the SAC system is the preferred and primary sourcing vehicle for VA hospitals. SAC awards require intensive product and value analysis vetting by a surgical committee and streamline the approval process by individual hospitals, making Symvess more readily available and visible across the entire VA system.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.